What’s Going on with Johnson & Johnson?
Johnson & Johnson (JNJ) announced July 1 that its single-shot COVID-19 vaccine demonstrated positive, long-lasting durability against the Delta (B.1.617.2) COVID-19 variant. Pre-market this morning, JNJ stock rose 0.33% to $166.50 a share.
What Does This Mean for JNJ?
According to Johnson & Johnson’s news release, data from two studies have now shown that the firm’s single-shot COVID-19 vaccine has demonstrated strong and long-lasting neutralizing antibody activity against the Delta variant, with persistent immune responses reported to last at least eight months. Furthermore, the studies indicate that the company’s vaccine generates a strong neutralizing antibody response, which does not decline, but rather improves over time.
“Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help protect the health of people globally,” Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., remarked. “We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant. This adds to the robust body of clinical data supporting our single-shot vaccine’s ability to protect against multiple variants of concern.”
JNJ has an Overall Score of 53. Find out what this means to you and get the rest of the rankings on JNJ!
Johnson & Johnson is the world’s largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
